GlobeImmune Announces Top Line Results From GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients
May 27, 2015 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - May 27, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced top line results from the GS-4774 Phase 2 study in patients with chronic hepatitis B on long term...
GlobeImmune Announces First Quarter 2015 Results and Corporate Highlights
May 14, 2015 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - May 14, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced its first quarter 2015 financial results and corporate highlights."We are pleased with the progress...
GlobeImmune Announces Opening of Randomized Phase 2 Chordoma Trial at National Cancer Institute
April 22, 2015 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - April 22, 2015) - GlobeImmune, Inc. today announced that a randomized Phase 2 clinical trial designed to investigate the safety and efficacy of GI-6301 in combination...
GlobeImmune Announces Program Updates and Financial Results for Full Year 2014
March 17, 2015 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - March 17, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM) today provided an update on the Company's business and clinical programs, and announced financial results for the full...
GlobeImmune to Present at the 27th Annual ROTH Conference
March 02, 2015 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - March 02, 2015) - GlobeImmune, Inc.,
(NASDAQ: GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the 27th Annual ROTH...
GlobeImmune to Present at the 17th Annual BIO CEO & Investor Conference
February 03, 2015 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - February 03, 2015) -
GlobeImmune, Inc.,
(NASDAQ: GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the 17th Annual BIO CEO...
GlobeImmune Announces Third Quarter 2014 Financial Results
November 12, 2014 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - November 12, 2014) - GlobeImmune, Inc. (NASDAQ: GBIM), today announced its third quarter 2014 financial results and corporate highlights."Following the completion of...
Updated Chordoma Data From Phase 1 Study of GI-6301 Presented at 2014 Connective Tissue Oncology Society (CTOS) Annual Meeting
October 17, 2014 06:30 ET
|
GlobeImmune, Inc.
BERLIN, GERMANY--(Marketwired - October 17, 2014) - GlobeImmune, Inc., today announced that updated results from eleven chordoma patients in the GI-6301 Phase 1 trial were presented at the 2014 CTOS...
GlobeImmune to Present at the 13th Annual BioInvestor Forum
September 30, 2014 07:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - September 30, 2014) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the 13th Annual BioInvestor...
GlobeImmune to Present at the 21st Annual NewsMakers in the Biotechnology Industry Investment Conference
September 18, 2014 07:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - September 18, 2014) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the 21st Annual BioCentury...